This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boehringer Ingelheim Pharmaceuticals Re-Signs To 10 Years At Matrix Corporate Center

DANBURY, Conn., April 5, 2013 /PRNewswire/ -- The Matrix Realty Group is pleased to announce Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), the world's largest privately held pharmaceutical company in the United States, has signed a ten-year lease extension at the Matrix Corporate Center (MCC), on Ridgebury Road in Danbury.

"We are honored to have been a part of what is likely the largest leasing transaction in New England this year," said Glen Nelson, CEO of Matrix Realty Group. "The quality of our amenities provides an office campus environment that has allowed our leasing efforts to continually indulge the leasing market," he continued. "To that end, we are currently in discussions with several large companies, which we anticipate bringing to the Matrix Corporate Center in the very near future."

Boehringer Ingelheim Pharmaceuticals, Inc. was founded in 1885, with their headquarters in Germany. The company employs 44,000 associates in 50 countries, with sales in excess of 17 billion dollars.  The focus of the company includes the therapeutic areas of cardiovascular disease, respiratory disease, disease of central nervous systems metabolic diseases, virological disease and oncology.

The lease was signed on February 1 st, 2013, encompassing 327,095 square feet for a ten year term through December 2022. 

Mike Brown, General Manager of Matrix Corporate Center, handled the lease transaction, with Trip Hoffman and Jay Hruska of Cushman & Wakefield in Stamford, CT representing Boehringer Ingelheim Pharmaceuticals.

"Boehringer Ingelheim's long term commitment to Matrix Corporate Center demonstrates the quality of our onsite owner/management team, full building services and amenity rich environment," said Brown. "There is no other building offering the extensive amenities and service, all inclusive at the price we offer."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.23 -1.00%
GOOG $697.34 0.72%
FB $117.97 0.46%
YHOO $35.93 -0.22%
TSLA $223.49 -3.80%


Chart of I:DJI
DOW 17,650.20 -100.71 -0.57%
S&P 500 2,050.15 -13.22 -0.64%
NASDAQ 4,724.0390 -39.1850 -0.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs